Results of the Call

Mostrar texto Ocultar texto
  • DATA 2024

    The CaixaResearch Health Call 2024 has awarded a total of 25.7 million € to 29 biomedical research projects, one of which was selected in collaboration with the Francisco Luzón Foundation, and three in collaboration with the Fundação para a Ciência e a Tecnologia (FCT) of the Ministério da Educação, Ciência e Inovação de Portugal.

    Below is a set of data related to the CaixaResearch Health Call 2024 and its resolution: the number of proposals submitted, preselected and selected by thematic area and type, as well as the territorial distribution of the budget for the selected projects.

    CAIXARESEARCH HEALTH CALL 2024

    Total budget

    €25,568,081.32

    Number of proposals submitted

    580

    Number of proposals evaluated

    535

    Number of proposals preselected

    90

    Number of projects selected

    29

    Success rate

    5,0 %

    Table 1. General information on the CaixaResearch Health Call 2024

     

    Figure 1. Budget distribution by territory

    Figure 1. Budget distribution by territory

    THEMATIC AREA

    PROPOSALS SUBMITTED

    ELIGIBLE PROPOSALS

    PRESELECTED PROPOSALS

    SELECTED PROJECTS

    Cardiovascular and metabolic diseases

    82

    76

    92,7 %

    18

    22,0 %

    5

    6,1 %

    Neurosciences

    156

    145

    92,9 %

    18

    11,5 %

    5

    3,2 %

    Infectious diseases

    87

    78

    89,7 %

    18

    20,7 %

    7

    8,0 %

    Oncology

    130

    120

    92,3 %

    18

    13,8 %

    6

    4,6 %

    Enabling technologies

    125

    116

    92,8 %

    18

    14,4 %

    6

    4,8 %

    Total

    580

    535

    92,2 %

    90

    15,5 %

    29

    5,0 %

    Table 2. Percentage of preselected proposals and selected projects with respect to the number of proposals submitted in each thematic area

    PROJECT LEADER

    PROPOSALS SUBMITTED

    ELIGIBLE PROPOSALS

    PRESELECTED PROPOSALS

    SELECTED PROJECTS

    SUCCESS RATE

    Women

    236

    220

    34

    11

    4,7 %

    Men

    338

    309

    55

    17

    5,0 %

    Others

    3

    3

    0

    0

    0,0 %

    Prefer not to say

    3

    3

    1

    1

    33,3 %

    Table 3. Results by gender

Evaluation process

Mostrar texto Ocultar texto
  • ELIGIBILITY PHASE

    • 580 proposals processed, of which:

       
      • 4 did not pass the format eligibility;

      • 41 did not pass the content eligibility, after being flagged by AI and confirmed by two evaluators.

    • 535 proposals went on to the evaluation phase.

  • REMOTE EVALUATION PHASE

    • The proposals were evaluated by 201 experts, at least three per project.

    • Assignment of the proposals to the evaluators was conducted through an AI-assisted matching process, taking into consideration the type of project (basic, clinical or translational) and its key words.

    • The final score for each project was adjusted based on that contained in the document entitled Eligibility and evaluation guidelines of the call.

  • INTERVIEW PHASE

    • The top 18 proposals in the remote evaluation for each thematic area were preselected for the interview phase.

    • Five selection committees were constituted, each of them made up of seven to 10 experts selected for their scientific excellence and area of expertise.

  • LIST

Summary of selected projects

Mostrar texto Ocultar texto


CODE

PROJECT TITLE

PROJECT LEADER

HOST ORGANIZATION

PARTNER ORGANIZATIONS

THEMATIC AREA

CATEGORY

BUDGET (€)

HR24-00001

Exploiting host free fatty acids to sterilize Mycobacterium tuberculosis infections

Tiago Beites

i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação

Radboud University

Infectious disease

HR
Consortium

693,011.00

HR24-00042

A new Pathway to Modulate T cell Activity

Marc Veldhoen

Gulbenkian Institute of Molecular Medicine

Associação AccelBio

Infectious disease

HR
Consortium

963,414.00

HR24-00056

Restoring vision by integrating optic nerve organoids in retinitis pigmentosa rat visual circuity

Pia Cosma

Fundació Centre de Regulació Genòmica (CRG)

Universidade do Minho

Neuroscience

HR
Consortium

997,293.00

HR24-00150

Generating stress-resistant β-cell for cell replacement therapy

Lorenzo Pasquali

Universitat Pompeu Fabra (UPF)

Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (Helmholtz Munich)

Cardiovascular and associated metabolic diseases

HR
Consortium

981,616.00

HR24-00152

Generation of humanized organs from human iPS cells

Xabier Aranguren

Fundación para la Investigación Médica Aplicada (FIMA/CIMA)

Università degli Studi di Padova and Universidad de Murcia

Cardiovascular and associated metabolic diseases

HR
Consortium

999,127.90

HR24-00174

Peptide-based systems as artificial compartments to diagnose non-Alzheimer Tauopathies diseases

Ana Pina

Universidade Nova de Lisboa

Universitat de Barcelona - Fundació Bosch i Gimpera and Centro Hospitalar Lisboa Occidental

Enabling Technologies

HR
Consortium

999,994.87

HR24-00279

Mapping metastasis plasticity

Roger Gomis

Fundació Institut de Recerca Biomèdica (IRB Barcelona)

Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer

Oncology

HR
Consortium

664,165.90

HR24-00288

Decoding trypanosome interactions with the host vasculature

Luisa Figueiredo

Gulbenkian Institute of Molecular Medicine

Universidade Católica Portuguesa

Infectious disease

HR
Consortium

998,850.00

HR24-00298

Bacteria-based LCOR therapy in lung metastasis and rational design of co-stimulatory molecules

Luis Felipe Serrano

Fundació Centre de Regulació Genòmica (CRG)

Fundació Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)

Enabling Technologies

HR
Consortium

1,000,000.00

HR24-00326

Engineering the mechanobiology of the immunocompetent tumor ecosystem

Xavier Trepat

Fundació Institut de Bioenginyeria de Catalunya

Fundació Institut de Recerca Biomèdica (IRB Barcelona) and Centre Internacional de Mètodes Numèrics a l'Enginyeria (CIMNE)

Enabling Technologies

HR
Consortium

998,200.00

HR24-00341

LncRNAs modulating DNA damage and repair: towards novel therapies for hepatocellular carcinoma

Puri Fortes

Fundación para la Investigación Médica Aplicada (FIMA/CIMA)

Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III and Consejo Superior de Investigaciones Científicas (CSIC)

Oncology

HR
Consortium

999,203.20

HR24-00445

Redox Metabolism as an Achilles’ Heel in Malaria Drug Discovery

Ruth Pérez

Consejo Superior de Investigaciones Científicas (CSIC)

Justus-Liebig-Universität Gießen and Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE

Infectious disease

HR
Consortium

999,400.00

HR24-00446

Exploring the PERK/STING axis in Pathological Inflammatory Conditions

Philippe Pierre

Universidade de Aveiro

N/A

Cardiovascular and associated metabolic diseases

HR
Single
Organization

499,931.66

HR24-00447

Targeting the Seeds of Relapse in Colorectal Cancer: Residual Disease and the Fibroblast Niche

Eduard Batlle

Fundació Institut de Recerca Biomèdica (IRB Barcelona)

N/A

Oncology

HR
Single
Organization

499,400.00

HR24-00528

Protein Aggregation in the Malaria Parasite: What for?

Xavier Fernàndez

Fundació Institut de Bioenginyeria de Catalunya

Universitat de Barcelona and Nanyang Technological University

Infectious disease

HR
Consortium

907,923.1

HR24-00578

New molecules harnessing targeted protein degradation for the treatment of Machado-Joseph disease

Patrícia Maciel

Universidade do Minho

Universidade do Porto; Ataxia UK and National Ataxia Foundation

Neuroscience

HR
Consortium

999,026.16

HR24-00581

Mitochondrial metabolism, at the heart of disease

Guadalupe Sabio

Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III

Universitat de València; Universidad de Santiago de Compostela and Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)

Cardiovascular and associated metabolic diseases

HR
Consortium

999,920.00

HR24-00585

Development of a Synthetic Viral-like Particle Delivery System for Precision In vivo Gene Therapy

Marc Güell

Universitat Pompeu Fabra (UPF)

N/A

Enabling Technologies

HR
Single
Organization

499,750.00

HR24-00604

Mito4Neuro: Integrative characterization of the mitochondrial DNA replisome in health and disease

Rafael Fernandez

Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III

Hospital 12 de Octubre Research Institute and Fundación IMDEA Nanociencia

Neuroscience

HR
Consortium

900,300.00

HR24-00641

Mechanisms of progression and therapeutic approaches to prevent/reverse MASLD to MASH transition

Antonio Vidal

Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe

Consorcio Centro de Investigación Biomédica en Red

Cardiovascular and associated metabolic diseases

HR
Consortium

999,959.3

HR24-00648

Spatiotemporal dynamics of organ-specific microenvironments in breast cancer metastasis

Ana Luisa Correia

Fundação D. Anna Sommer Champalimaud e Dr. Carlos Montez Champalimaud

Tel Aviv University

Oncology

HR
Consortium

997,610.0

HR24-00672

Deep mutational scanning of SOD1 to map mechanisms of toxicity and test novel therapeutics

Benedetta Bolognesi

Fundació Institut de Bioenginyeria de Catalunya

The Royal Melbourne Hospital and University of Wollongong

Enabling Technologies

HR
Consortium

981,070.19

HR24-00686

A High-Resolution Functional Genomics Approach to Inform Precision Medicine for Fungal Disease

Agostinho Carvalho

Universidade do Minho

Radboud university medical center Nijmegen and Fundación Universitaria San Pablo-CEU

Infectious diseases

HR
Consortium

999,898.43

HR24-00788

Brain Inflammation in adrenoleukodystrophy: from drivers to treatments

Aurora Pujol

Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)

Fundació Institut de Recerca Contra la Leucèmia Josep Carreras; Universitat de Barcelona and Asociación Española Contra la Leucodistrofia

Neuroscience

HR
Consortium

999,782.47

HR24-00927

Improving Brain Arteriovenous Malformation Cure with local Antioncogenic Nanoparticle Embolization

Marc Ribó

Fundació Hospital Universitari Vall d´Hebron - Institut de Recerca (VHIR)

Universitat de Barcelona; Consorcio Centro de Investigación Biomédica en Red and Fundació Institut Català de Nanociència i Nanotecnologia

Neuroscience

HR
Consortium

998,684.72

HR24-00929

Novel regulators of gamma-delta T cell subset differentiation and activation in infection

Bruno Silva-Santos

Gulbenkian Institute of Molecular Medicine

N/A

Infectious disease

HR
Single
Organization

500,000.00

HR24-00968

Precision ImmuneNanoTherapy targeting tumor-immune-stroma interactions against pancreatic cancer

María Jesús Vicent

Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe

FARM-ID - Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento and Tel Aviv University

Enabling technologies

HR
Consortium

999,999.4

HR24-00980

DNA topology and topoisomerases during oncogenesis: mechanisms and therapeutic opportunities

Felipe Cortés

Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III

N/A

Oncology

HR
Single
Organization

499,000.00

HR24-01000

Uncovering resistance mechanism to CAR-T cells via deep learning in scRNA-seq for improved therapies

Felipe Prosper

Universidad de Navarra - Universidad de Navarra

Fundación para la Investigación Médica Aplicada (FIMA/CIMA) and Weizmann Institute of Science

Oncology

HR
Consortium

991,550.00